imipramine has been researched along with Alzheimer Disease in 54 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Imipramine is a kind of tricyclic antidepressant with reported anti-inflammatory and anti-oxidant effects in the brain." | 1.62 | Imipramine alleviates memory impairment and hippocampal apoptosis in STZ-induced sporadic Alzheimer's rat model: Possible contribution of MAPKs and insulin signaling. ( Ahmadiani, A; Askari, S; Dargahi, L; Ghasemi, R; Javadpour, P; Rashidi, FS, 2021) |
| "Considering the complex etiology of Alzheimer's disease (AD), multifunctional agents may be beneficial for the treatment of this disease." | 1.46 | DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy. ( Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y, 2017) |
| "Imipramine significantly prevented memory deficits caused by Abeta25-35 in the water-maze and Y-maze tests, and inhibited the TNF-alpha increase in the frontal cortex." | 1.36 | Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease. ( Chavant, F; Deguil, J; Fauconneau, B; Ingrand, I; Lafay-Chebassier, C; Milin, S; Pain, S; Pérault-Pochat, MC, 2010) |
| "Imipramine promotes the non-amyloidogenic route of APP processing via stimulatory effects on PKC." | 1.33 | Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro. ( Bjelik, A; Hugyecz, M; Janka, Z; Kálmán, J; Kása, P; Pákáski, M, 2005) |
| "The patients with probable Alzheimer's disease showed no alteration in platelet-tritiated imipramine binding." | 1.27 | Marked reduction in the number of platelet-tritiated imipramine binding sites in geriatric depression. ( Bissette, G; Blazer, DG; Knight, DL; Krishnan, RR; Melville, ML; Nemeroff, CB; Slotkin, TA, 1988) |
| "Since serotonin system defects occur in Alzheimer's disease (AD), and decreased brain 3H-imipramine binding density, and increased brain and platelet MAO activity are reported also, we studied platelet 3H-imipramine binding density (Bmax) and platelet MAO activity in AD outpatients without antecedent psychiatric disorder." | 1.27 | Platelet tritiated imipramine binding and MAO activity in Alzheimer's disease patients with agitation and delusions. ( Chui, HC; Fredrickson, ER; Pollock, VE; Schneider, LS; Severson, JA; Sloane, RB, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (22.22) | 18.7374 |
| 1990's | 2 (3.70) | 18.2507 |
| 2000's | 5 (9.26) | 29.6817 |
| 2010's | 31 (57.41) | 24.3611 |
| 2020's | 4 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Marco-Contelles, J | 1 |
| León, R | 3 |
| de los Ríos, C | 1 |
| Samadi, A | 1 |
| Bartolini, M | 3 |
| Andrisano, V | 3 |
| Huertas, O | 2 |
| Barril, X | 1 |
| Luque, FJ | 3 |
| Rodríguez-Franco, MI | 6 |
| López, B | 3 |
| López, MG | 4 |
| García, AG | 3 |
| Carreiras, Mdo C | 1 |
| Villarroya, M | 4 |
| Camps, P | 1 |
| Formosa, X | 1 |
| Galdeano, C | 1 |
| Muñoz-Torrero, D | 3 |
| Ramírez, L | 1 |
| Gómez, E | 1 |
| Isambert, N | 1 |
| Lavilla, R | 2 |
| Badia, A | 1 |
| Clos, MV | 2 |
| Mancini, F | 1 |
| Arce, MP | 4 |
| Dafni, T | 1 |
| González-Muñoz, GC | 2 |
| Pérez, C | 4 |
| Conde, S | 3 |
| Romero, A | 1 |
| del Barrio, L | 1 |
| Martín-de-Saavedra, MD | 1 |
| Egea, J | 2 |
| Tang, H | 3 |
| Zhao, LZ | 1 |
| Zhao, HT | 2 |
| Huang, SL | 1 |
| Zhong, SM | 2 |
| Qin, JK | 1 |
| Chen, ZF | 2 |
| Huang, ZS | 1 |
| Liang, H | 2 |
| Wang, ZY | 1 |
| Di Pietro, O | 1 |
| Pérez-Areales, FJ | 2 |
| Juárez-Jiménez, J | 1 |
| Espargaró, A | 2 |
| Pérez, B | 3 |
| Sabaté, R | 2 |
| Sang, Z | 11 |
| Li, Y | 11 |
| Qiang, X | 10 |
| Xiao, G | 7 |
| Liu, Q | 2 |
| Tan, Z | 12 |
| Deng, Y | 11 |
| Luo, L | 6 |
| Wei, S | 1 |
| Chen, W | 1 |
| Qin, J | 1 |
| Huangli, Y | 1 |
| Wang, L | 1 |
| Shen, Y | 1 |
| Yang, X | 5 |
| Zheng, Y | 4 |
| Cao, Z | 6 |
| Su, F | 2 |
| Ai, J | 1 |
| Xu, R | 5 |
| Song, Q | 5 |
| Monjas, L | 1 |
| Gil, C | 1 |
| Pan, W | 2 |
| Wang, K | 8 |
| Ma, Q | 4 |
| Yu, L | 4 |
| Yang, Y | 1 |
| Bai, P | 2 |
| Leng, C | 1 |
| Xu, Q | 1 |
| Li, X | 1 |
| Liu, W | 7 |
| Wang, H | 4 |
| Ye, M | 2 |
| Han, X | 2 |
| Jiang, N | 1 |
| Huang, Q | 1 |
| Liu, J | 1 |
| Liang, N | 1 |
| Li, Q | 2 |
| Xie, SS | 1 |
| Yang, J | 2 |
| Zhang, X | 2 |
| Liu, H | 4 |
| Yang, Z | 2 |
| Hepnarova, V | 1 |
| Korabecny, J | 1 |
| Matouskova, L | 1 |
| Jost, P | 1 |
| Muckova, L | 1 |
| Hrabinova, M | 1 |
| Vykoukalova, N | 1 |
| Kerhartova, M | 1 |
| Kucera, T | 1 |
| Dolezal, R | 1 |
| Nepovimova, E | 1 |
| Spilovska, K | 1 |
| Mezeiova, E | 1 |
| Pham, NL | 1 |
| Jun, D | 1 |
| Staud, F | 1 |
| Kaping, D | 1 |
| Kuca, K | 1 |
| Soukup, O | 1 |
| Reis, J | 1 |
| Cagide, F | 1 |
| Valencia, ME | 1 |
| Teixeira, J | 1 |
| Bagetta, D | 1 |
| Uriarte, E | 1 |
| Oliveira, PJ | 1 |
| Ortuso, F | 1 |
| Alcaro, S | 1 |
| Borges, F | 1 |
| Tian, C | 1 |
| Li, W | 1 |
| He, Y | 1 |
| Ye, C | 1 |
| Shi, J | 4 |
| Zhang, P | 3 |
| Turcu, AL | 2 |
| Barniol-Xicota, M | 1 |
| Pont, C | 1 |
| Pivetta, D | 1 |
| De Simone, A | 1 |
| Sureda, FX | 2 |
| Vázquez, S | 2 |
| Zhu, G | 1 |
| Yang, D | 1 |
| Fan, X | 1 |
| Zhang, Z | 1 |
| Cheng, X | 1 |
| Zhang, Q | 1 |
| Zheng, C | 1 |
| Cheng, Y | 1 |
| Lu, X | 1 |
| Companys-Alemany, J | 1 |
| Phillips, MB | 1 |
| Patel, DS | 1 |
| Griñán-Ferré, C | 1 |
| Loza, MI | 1 |
| Brea, JM | 1 |
| Soto, D | 1 |
| Kurnikova, MG | 1 |
| Johnson, JW | 1 |
| Pallàs, M | 1 |
| Johnson, NR | 1 |
| Wang, AC | 1 |
| Coughlan, C | 1 |
| Sillau, S | 1 |
| Lucero, E | 1 |
| Viltz, L | 1 |
| Markham, N | 1 |
| Allen, C | 1 |
| Dhanasekaran, AR | 1 |
| Chial, HJ | 1 |
| Potter, H | 1 |
| Crivelli, SM | 1 |
| Quadri, Z | 1 |
| Vekaria, HJ | 1 |
| Zhu, Z | 1 |
| Tripathi, P | 1 |
| Elsherbini, A | 1 |
| Zhang, L | 1 |
| Sullivan, PG | 1 |
| Bieberich, E | 1 |
| Javadpour, P | 1 |
| Askari, S | 1 |
| Rashidi, FS | 1 |
| Dargahi, L | 1 |
| Ahmadiani, A | 1 |
| Ghasemi, R | 1 |
| Chavant, F | 1 |
| Deguil, J | 1 |
| Pain, S | 1 |
| Ingrand, I | 1 |
| Milin, S | 1 |
| Fauconneau, B | 1 |
| Pérault-Pochat, MC | 1 |
| Lafay-Chebassier, C | 1 |
| Nardi, M | 1 |
| Anwander, M | 1 |
| Rüegger-Frey, B | 1 |
| Bopp-Kistler, I | 1 |
| Pákáski, M | 1 |
| Bjelik, A | 1 |
| Hugyecz, M | 1 |
| Kása, P | 1 |
| Janka, Z | 1 |
| Kálmán, J | 1 |
| Bowen, DM | 1 |
| Allen, SJ | 1 |
| Benton, JS | 1 |
| Goodhardt, MJ | 1 |
| Haan, EA | 1 |
| Palmer, AM | 1 |
| Sims, NR | 1 |
| Smith, CC | 1 |
| Spillane, JA | 1 |
| Esiri, MM | 1 |
| Neary, D | 1 |
| Snowdon, JS | 1 |
| Wilcock, GK | 1 |
| Davison, AN | 1 |
| Perry, EK | 1 |
| Marshall, EF | 1 |
| Blessed, G | 1 |
| Tomlinson, BE | 1 |
| Perry, RH | 1 |
| Okiishi, CG | 1 |
| Paradiso, S | 1 |
| Robinson, RG | 1 |
| Teri, L | 2 |
| Reifler, BV | 2 |
| Veith, RC | 1 |
| Barnes, R | 2 |
| White, E | 2 |
| McLean, P | 2 |
| Raskind, M | 2 |
| Bonuccelli, U | 1 |
| Piccini, P | 1 |
| Marazziti, D | 1 |
| Cassano, GB | 1 |
| Muratorio, A | 1 |
| Galzin, AM | 1 |
| Davous, P | 1 |
| Roudier, M | 1 |
| Lamour, Y | 1 |
| Poirier, MF | 1 |
| Langer, SZ | 1 |
| Veith, R | 1 |
| Sandifer, MG | 1 |
| Nemeroff, CB | 1 |
| Knight, DL | 1 |
| Krishnan, RR | 1 |
| Slotkin, TA | 1 |
| Bissette, G | 1 |
| Melville, ML | 1 |
| Blazer, DG | 1 |
| Schneider, LS | 1 |
| Severson, JA | 1 |
| Chui, HC | 1 |
| Pollock, VE | 1 |
| Sloane, RB | 1 |
| Fredrickson, ER | 1 |
| Weizman, R | 1 |
| Dick, J | 1 |
| Mosek, A | 1 |
| Tyano, S | 1 |
| Rehavi, M | 1 |
| Suranyi-Cadotte, BE | 1 |
| Gauthier, S | 1 |
| Lafaille, F | 1 |
| DeFlores, S | 1 |
| Dam, TV | 1 |
| Nair, NP | 1 |
| Quirion, R | 1 |
| Marcusson, JO | 1 |
| Alafuzoff, I | 1 |
| Bäckström, IT | 1 |
| Ericson, E | 1 |
| Gottfries, CG | 1 |
| Winblad, B | 1 |
| D'Amato, RJ | 1 |
| Zweig, RM | 1 |
| Whitehouse, PJ | 1 |
| Wenk, GL | 1 |
| Singer, HS | 1 |
| Mayeux, R | 1 |
| Price, DL | 1 |
| Snyder, SH | 1 |
1 review available for imipramine and Alzheimer Disease
| Article | Year |
|---|---|
Gender differences in depression associated with neurologic illness: clinical correlates and pharmacologic response.
Topics: Alzheimer Disease; Amitriptyline; Antidepressive Agents, Tricyclic; Depression; Epilepsy; Female; Hu | 2001 |
2 trials available for imipramine and Alzheimer Disease
| Article | Year |
|---|---|
Imipramine in the treatment of depressed Alzheimer's patients: impact on cognition.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Attention; Attitude; Cognition; Depressive Disorder; | 1991 |
Double-blind trial of imipramine in Alzheimer's disease patients with and without depression.
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Female; | 1989 |
51 other studies available for imipramine and Alzheimer Disease
| Article | Year |
|---|---|
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholines | 2009 |
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases | 2009 |
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cataly | 2009 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cel | 2011 |
Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Aporphines; Blood- | 2011 |
Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Binding Sites; Blood-Bra | 2012 |
Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cholinesterases; Dose-Response | 2014 |
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Blood-Brain Barrier; Butyr | 2015 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; C | 2016 |
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Autophagy; Cholinesteras | 2016 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; D | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inh | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Bloo | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors | 2017 |
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Don | 2017 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholine | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholin | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Chol | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood- | 2017 |
Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell L | 2018 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Surviva | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Br | 2018 |
The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line; Cholinesterase I | 2018 |
Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
Topics: Alzheimer Disease; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Chromones; Drug | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N | 2018 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cho | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyry | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase I | 2019 |
A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
Topics: Acetylcholinesterase; Adamantane; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitor | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Developm | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Tr | 2019 |
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Disease Models, Animal; Memantine; Mice; Recepto | 2022 |
Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer's disease cognition.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E4; Catalysis; Cognition; Humans; Imipramin | 2022 |
Inhibition of acid sphingomyelinase reduces reactive astrocyte secretion of mitotoxic extracellular vesicles and improves Alzheimer's disease pathology in the 5xFAD mouse.
Topics: Alzheimer Disease; Animals; Astrocytes; Ceramides; Extracellular Vesicles; Imipramine; Mice; Sphingo | 2023 |
Imipramine alleviates memory impairment and hippocampal apoptosis in STZ-induced sporadic Alzheimer's rat model: Possible contribution of MAPKs and insulin signaling.
Topics: Adrenergic Uptake Inhibitors; Alzheimer Disease; Animals; Antibiotics, Antineoplastic; Behavior, Ani | 2021 |
Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition; Diseas | 2010 |
[There's not only Alzheimer's disease].
Topics: Accidental Falls; Aged; Alzheimer Disease; Antidepressive Agents; Cognition Disorders; Comorbidity; | 2012 |
Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antidepressive Ag | 2005 |
Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease.
Topics: Acetylcholine; Aged; Alzheimer Disease; Atrophy; Brain; Carrier Proteins; Cerebral Cortex; Dementia; | 1983 |
Decreased imipramine binding in the brains of patients with depressive illness.
Topics: Aged; Alzheimer Disease; Binding Sites; Brain; Cerebral Cortex; Depressive Disorder; Female; Hippoca | 1983 |
Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Blood Platelets; Female; Humans; Imipramine; Male; Middle Aged; Monoamine O | 1990 |
Platelet [3H]-imipramine binding is not modified in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Blood Platelets; Carrier Proteins; Depressive Disorder; | 1989 |
Depression in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Depression; Humans; Imipramine | 1989 |
Imipramine for patients with Alzheimer's disease with and without depression.
Topics: Alzheimer Disease; Depression; Humans; Imipramine | 1989 |
Marked reduction in the number of platelet-tritiated imipramine binding sites in geriatric depression.
Topics: Adolescent; Adult; Age Factors; Aged; Alzheimer Disease; Blood Platelets; Carrier Proteins; Depressi | 1988 |
Platelet tritiated imipramine binding and MAO activity in Alzheimer's disease patients with agitation and delusions.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Blood Platelets; Carrier Proteins; Delusions; Female; Hu | 1988 |
Unaltered platelet [3H]-imipramine binding in dementia of the Alzheimer type.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Blood Platelets; Carrier Proteins; Female; Humans; Imipr | 1988 |
Platelet 3H-imipramine binding distinguishes depression from Alzheimer dementia.
Topics: Age Factors; Aged; Alzheimer Disease; Blood Platelets; Carrier Proteins; Depressive Disorder; Diagno | 1985 |
5-Hydroxytryptamine-sensitive [3H]imipramine binding of protein nature in the human brain. II. Effect of normal aging and dementia disorders.
Topics: Aged; Aging; Alzheimer Disease; Brain; Dementia; Humans; Imipramine; Middle Aged; Nerve Tissue Prote | 1987 |
Aminergic systems in Alzheimer's disease and Parkinson's disease.
Topics: Alzheimer Disease; Biogenic Amines; Brain; Choline O-Acetyltransferase; Citalopram; Humans; Imiprami | 1987 |